<p>Dual-Mode Contrast Agents with RGD-Modified Polymer for Tumour-Targeted US/NIRF Imaging</p>

Abstract

Background Cancer diagnosis and treatment during the early stages of disease remain extremely challenging clinical tasks. The development of effective multimode contrast agents could greatly facilitate the early detection of cancer. Materials and Methods We prepared dual-mode contrast agents using a biotin/avidin bioamplification system. Through in vivo and in vitro experiments, we verified the imaging performance of this contrast agents in both fluorescence and ultrasound and its targeting specificity for MDA-MB-231 cells. Results The RGD peptide-labelled microbubbles showed excellent targeting of αvβ3 integrin expressed by MDA-MB-231 cells in vitro and in vivo. The signal intensity and time duration of ultrasound imaging using these particles were superior to those obtained with a typical ultrasound contrast agent in the clinic. The tumour areas also demonstrated high Cy5.5 accumulation by fluorescence imaging. Conclusion The results show that this targeted dual-mode imaging system yields outstanding US/NIRF imaging results, possibly allowing the early clinical diagnosis of cancer.

MR/NIRF Dual-Mode Imaging of αvβ3 Integrin-Overexpressing Tumors Using a Lipopeptide-Based Contrast Agent

“…The advantages of NIRF imaging include a high spatial and temporal resolution, which can compensate for the limitations of MRI, ,,, and NIRF can assist surgeons in filling the gap between preoperative imaging and intraoperative reality. − Accordingly, we added the fluorescent dye Cy5.5 to the contrast agent to construct the MR/NIRF dual-mode targeted contrast agent cRGD-Liposome-Cy5.5.…”

“…Integrin αvβ3 is a member of the family of transmembrane cell surface molecules that is highly expressed in tumor blood vessels and overexpressed in many solid tumors . The arginine-glycine-aspartate (Arg-Gly-Asp, RGD) sequence which specifically binds to integrin αvβ3 is commonly used as a tumor tracer to visualize tumors by various imaging modalities. , …”

“…The advantages of near-infrared fluorescence (NIRF) imaging including real-time imaging and high sensitivity can mitigate the limitations of MRI. ,, In addition, NIRF imaging allows tumors to be accurately visualized in vivo and vitro; as a result, NIRF imaging can assist surgeons in filling the gap between preoperative imaging and intraoperative reality. − Therefore, we added Cy5.5 to the contrast agent for NIRF imaging.…”

“…7 The arginine-glycine-aspartate (Arg-Gly-Asp, RGD) sequence which specifically binds to integrin αvβ3 is commonly used as a tumor tracer to visualize tumors by various imaging modalities. 8,9 Currently, Gd(III)-based contrast agents and superparamagnetic iron oxide (SPIO) are the most common MR contrast agents. Gd and iron change the MR signals by shortening the longitudinal relaxation time (T1) and the transverse relaxation time (T2).…”

A Dual‐Mode Imaging Nanoparticle Probe Targeting PD‐L1 for Triple‐Negative Breast Cancer

“…Molecular imaging enables noninvasive monitoring of changes in potential molecular targets of tumor cells. In recent years, contrast agents have been developed to detect tumors and improve treatment efficacy, involving recognizing specific receptors on the surface of tumor cells, such as α v β 3 [9,10] and EGFR [11,12], which have yielded excellent results. It has been established that near-infrared fluorescence imaging (NIRF) has excellent sensitivity, specificity, and safety profile.…”